Upgrade: Phase 1 combination trial of the NaPi2b-directed dolaflexin antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi; XMT-1536) in patients with ovarian cancer (588) von Lakhani, Nehal, Burns, Timothy, Barve, Minal, Edenfield, Jeffery, Hays, John, Zarwan, Corrine, Werner, Theresa, Anderson, Charles, Buscema, Joseph, Bernardo, Patricia, Keeton, Erika, Carrington, Cassandra, Burger, Robert

Volltext

UPGRADE-A: Phase 1 expansion trial of the NaPi2b-directed antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi) in combination with carboplatin in patients with high-grade ser... von Hays, John L., Friedman, Claire Frances, Lakhani, Nehal, Anderson, Charles K, Buscema, Joseph, Duska, Linda R., Hamilton, Erika P., Taylor, Sarah E., Carrington, Cassandra, Burger, Robert Allen, Werner, Theresa Louise

Volltext

32 UPGRADE: phase 1 combination trial of the NaPi2b-directed antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi; XMT-1536) in patients with ovarian cancer von Werner, Theresa L., Lakhani, Nehal, Edenfield, William, Hays, John, Zarwan, Corrine, Buscema, Joseph, Burns, Timothy, Carrington, Cassandra, Keeton, Erika K., Burger, Robert A., Anderson, Charles

Volltext

Host variation in type I interferon signaling genes (MX1), C–C chemokine receptor type 5 gene, and major histocompatibility complex class I alleles in treated HIV+ noncontrollers p... von Siegel, David A., Thanh, Cassandra, Wan, Eunice, Hoh, Rebecca, Hobbs, Kristen, Pan, Tony, Gibson, Erica A., Kroetz, Deanna L., Martin, Jeffrey, Hecht, Frederick, Pilcher, Christopher, Martin, Maureen, Carrington, Mary, Pillai, Satish, Busch, Michael P., Stone, Mars, Levy, Claire N., Huang, Meei-Li, Roychoudhury, Pavitra, Hladik, Florian, Jerome, Keith R., Kiem, Hans-Peter, Henrich, Timothy J., Deeks, Steven G., Lee, Sulggi A.

Volltext